Maravai LifeSciences Holdings, Inc.
Every calculator, already run for MRVI
Open the full toolkit →You have the numbers on MRVI. Get the argument.
A written report on which of these readings actually decide the outcome for Maravai LifeSciences Holdings, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
9 analysts covering MRVIAnalyst Price Target Disagreement for Maravai LifeSciences Holdings, Inc.
Wall Street's bull case implies +15% from the current price; the bear case implies -7%. Analysts are relatively aligned on MRVI's range.
Ownership & short interest
Insider Trading Activity for MRVI
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also…
MRVI — frequently asked
Is MRVI a buy right now?
Wall Street's consensus rating on Maravai LifeSciences Holdings, Inc. is Buy across 9 analysts, with a mean price target of $7.42 (+6% vs. the current $6.97). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is MRVI's next earnings date?
Maravai LifeSciences Holdings, Inc. is next scheduled to report earnings around Nov 5, 2026. A full MRVI research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Maravai LifeSciences Holdings, Inc.?
Analysts covering Maravai LifeSciences Holdings, Inc. (MRVI) range from a bear-case target of $6.50 to a bull-case high of $8.00, with a mean consensus target of $7.42 across 6 analysts. The spread of $1.50 (22% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Maravai LifeSciences Holdings, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Maravai LifeSciences Holdings, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MRVI research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Maravai LifeSciences Holdings, Inc., in minutes. 3 free reports included with every account — no credit card required.